Actinomycin D (or cycloheximide) administered prior to radioactive 25-hydroxycholecalciferol blocks the metabolism of 25-hydroxycholecalciferol to polar metabolites that accumulate in intestinal tissue, while it does not prevent the 25-hydroxylation of vitamin D, in the liver. Actinomycin D given after radioactive 25-hydroxycholecalciferol does not inhibit 25-hydroxycholecalciferol metabolism. These results indicate that 25-hydroxycholecalciferol must interact with the nuclei of cells to bring about the production of an enzyme(s) that converts it to its polar metabolites.
In 1964 it was demonstrated in this laboratory that vitamin D is converted to biologically active metabolites (1) . However, it was not until the work of Lund and DeLuca (2) that metabolites more biologically active than the parent vitamin were unequivocally demonstrated. One of these metabolites was soon identified as an ester of vitamin D and long-chain fatty acids (3) and was extensively studied (4, 5) . Its physiologic significance, however, seemed minor since its concentration did not change in the tissues regardless of dose or the length of time after the dose. A polar metabolite fraction was discovered (2) , however, that was more effective in the cure of rickets in rats than was the parent vitamin. This fraction was subsequently shown to act more rapidly in inducing intestinal calcium transport than vitamin D3 itself (6) . Furthermore, it was shown by Ponchon and DeLuca (7) that this fraction could be subfractionated into at least seven radioactive components, only one of which exhibited an enhanced ability to cure rickets in rats. This compound was subsequently isolated in pure form from the plasma of pigs and identified as 25-hydroxycholecalciferol (25-HCC) (8, 9) . It was synthesized (10) , and its biopotency was tested in a wide variety of systems (11) . It proved to be not only much more active than vitamin D3, but it acted more rapidly in all systems. Most revealing, however, was the fact that it acts in isolated target organs for vitamin D action; namely, bone and intestine, whereas large amounts of vitamin D3 are ineffective (12, 13) . These results, and other chromatographic results (7), provide very strong evidence that the 25-HCC represents the circulating active form, or the hormonal form, of vitamin D3. 25-Hydroxyergocalciferol was also isolated and identified in a similar fashion (14) . More recently, Cousins et al. (15, 16) have shown that 25-HCC is metabolized very rapidly to metabolites more polar than 25-HCC. Previous work (7, 17, 18) (20) have also found some biological activity in this fraction. The biological activity of the polar metabolite [Peak V of DeLuca and coworkers (7, 15, 16, 20) , Peak (2) .
In the experiments related to Fig. 1 , rats were killed by decapitation and their blood was collected. The serum was harvested after centrifugation. It was extracted with methanol and chloroform (2) and the extract was used for chromatography.
Chromatography was performed on columns of silicic acid (23) . The exact methods used are described in the figure legends. RESULTS The first series of experiments was designed to test the possibility that the production of 25-HCC by the liver 25-hydroxylase might be sensitive to actinomycin D and, hence, involve an induction of the hydroxylase. Results shown in Fig. 1 demonstrate clearly that the prior administration of actinomycin D had no influence whatsoever on the appearance of 25-HCC in the plasma when [1,2-3H]vitamin D3 was injected. Continued investigation of this point provided confirmatory evidence. As might be expected, administration of actinomycin D to rats prior to the administration of tritiated 25-HCC did not diminish the amount of radioactivity in the intestine (Fig. 2) .
In all cases the intestine accumulated approximately 4% of the administered dose. However, the surprising result was observed that the prior administration of actinomycin D prevented almost entirely the conversion of 25-HCC to the peak V metabolite described by Cousins et al. (15, 16) . This observation was repeated many times, and the time course of appearance of the peak V metabolite in the presence and absence of actinomycin D is shown in Figure 3 . There is little doubt that actinomycin D prevented the appearance of the metabolite throughout the course of the experiment. However, a small amount of the peak V metabolite persisted. In an effort to eliminate completely the small amount of persistent metabolite, the dose of radioactive 25-HCC was reduced to 1/1o of that in the previous experiment. Again, prior administration of actinomycin D prevented the conversion of 25-HCC to the peak V metabolite. A very small amount of the peak V metabolite, however, did persist in the actinomycin D-treated animal (Fig. 4) .
We Fig. 5 , demonstrate that if actinomycin D is given after 25-HCC, the production of the peak V metabolite is no longer inhibited. Thus, actinomycin D is acting in its expected fashion; that is, it blocks some early event responsible for the metabolism of 25-HCC to the peak V metabolite. This experiment makes unlikely the possibility that actinomycin D might be directly inhibiting this conversion.
To further examine the question of the specificity of this effect of actinomycin D, the effect of prior administration of cycloheximide, a protein synthesis inhibitor, on the metabolism of 25-HCC to the peak V metabolite was also examined. The results shown in Fig. 6 demonstrate that prior administration of cycloheximide completely eliminates the production of the peak V metabolite from 25-HCC. Furthermore, in experiments not shown, cycloheximide did not prevent peak V formation if it was given after [3H]25-HCC. These results suggest that de novo synthesis of RNA and protein are required for the metabolism of 25-HCC to its more polar metabolites found in the intestine.
DISCUSSION
The results of the present investigation reveal that 25 Chromatography was performed as in Fig. 4 , and the rats were killed 8 hr after they had received [3H] 25-HCC.
workers (24, 25) , or the calcium-dependent ATPase described in this laboratory (26, 27) , or both. It is, therefore, possible that the actinomycin D-sensitive event in vitamin D action on intestine described several years ago by us (28, 29) and others (30) is the conversion of 25-HCC to its tissue-active form (peak V).
